share_log

Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33

Benzinga ·  May 8 14:03

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $42 to $33.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment